Nautilus Biotechnology, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Unaudited results are compared with Q1 2022. Nautilus is a development-stage proteomics company; it has no products available for commercial sale and reported no revenue.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 / prior date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $10.9 million | $9.7 million |
| General and administrative expense | $7.2 million | $6.4 million |
| Total operating expenses | $18.1 million | $16.0 million |
| Interest income | $3.1 million | $0.3 million |
| Net loss | $15.0 million | $15.8 million |
| Net loss per share, basic and diluted | $0.12 | $0.13 |
| Net cash used in operating activities | $12.5 million | $12.3 million |
| Cash, cash equivalents and short-term investments | $167.3 million | — |
| Cash, cash equivalents and all investments | $302.0 million | — |
At March 31, 2023, total assets were $345.9 million, total liabilities $42.2 million, and stockholders’ equity $303.7 million. The balance sheet included $37.3 million of operating lease liabilities; the filing reports no financial borrowings. Net loss margin is not meaningful because the company had no revenue.
Changes versus Q1 2022
- Operating expenses rose 13%: R&D increased $1.2 million and G&A increased $0.8 million, principally reflecting higher compensation and related costs.
- Net loss narrowed by $0.8 million, despite higher operating costs, primarily because interest income increased $2.8 million as market interest rates rose.
- Operating cash use was broadly similar, increasing $0.2 million to $12.5 million. Investing cash flow shifted from $15.2 million provided to $13.5 million used, mainly reflecting purchases of marketable securities net of maturities.
- Unrealized gains on available-for-sale securities contributed $0.9 million of other comprehensive income in Q1 2023, versus a $0.4 million loss in Q1 2022.
Outlook, risks and contingencies
- Management expects existing cash, cash equivalents and short-term investments to fund planned operating expenses and capital expenditures for at least 12 months. It expects significant losses and negative operating cash flows to continue, and says additional capital may be needed; financing may be unavailable or dilutive.
- The company is in the collaboration and validation phase of its planned three-phase commercial launch. It anticipates meaningful early-access engagements and associated revenue beginning in early 2024, followed by a broader launch in mid-2024. These are forward-looking expectations, not guaranteed outcomes.
- The platform remains under development and requires scientific and technical validation. Key risks include delays, customer adoption, manufacturing scale-up, reliance on third parties and single-source suppliers, competition, intellectual-property challenges, and potential future regulatory requirements.
- The filing cites prior supply disruptions and continuing uncertainty from economic conditions, inflation, interest rates, geopolitical events, and financial-market instability. A hypothetical 100-basis-point interest-rate change would have changed the fair value of marketable debt securities by $2.3 million; the effect would be realized only if securities were sold before maturity.
- Open purchase commitments were $1.4 million, expected to be received over the next 12 months. Future minimum operating lease payments totaled $51.4 million. Management reported no pending legal matter expected to have a material adverse effect.
- Disclosure controls and procedures were assessed as effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Progress against the stated early-access and mid-2024 broader-launch timelines, including platform performance validation and collaboration outcomes.
- Quarterly cash burn and the distinction between $167.3 million of cash, cash equivalents and short-term investments and $302.0 million including long-term investments.
- Whether revenue-generating commercialization, manufacturing capacity, and supply arrangements develop as planned, particularly given single-source dependencies.
- Future financing requirements and potential dilution, as well as stock-based compensation and the 13.6 million outstanding stock options reported at quarter-end.
- Lease obligations, regulatory status of any future products or uses, and any developments in intellectual-property or other material contingencies.